Exjade is a Oral Tablet, For Suspension in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Deferasirox.
| Product ID | 0078-0468_12e80115-bfb7-4292-89cc-e696a3c6c325 | 
| NDC | 0078-0468 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Exjade | 
| Generic Name | Deferasirox | 
| Dosage Form | Tablet, For Suspension | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2005-11-30 | 
| Marketing Category | NDA / NDA | 
| Application Number | NDA021882 | 
| Labeler Name | Novartis Pharmaceuticals Corporation | 
| Substance Name | DEFERASIROX | 
| Active Ingredient Strength | 125 mg/1 | 
| Pharm Classes | Iron Chelating Activity [MoA],Iron Chelator [EPC],Cytochrome P450 3A4 Inducers [MoA],Cytochrome P450 2C8 Inhibitors [MoA],Cytochrome P450 1A2 Inhibitors [MoA] | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2022-12-31 | 
| Marketing Start Date | 2005-11-30 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| Marketing Category | NDA | 
| Application Number | NDA021882 | 
| Product Type | HUMAN PRESCRIPTION DRUG | 
| Billing Unit | EA | 
| Marketing Start Date | 2005-11-30 | 
| Ingredient | Strength | 
|---|---|
| DEFERASIROX | 125 mg/1 | 
| SPL SET ID: | 3495a70c-870c-4968-940e-8baea152cf85 | 
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 0078-0468 | Exjade | deferasirox | 
| 0078-0469 | Exjade | deferasirox | 
| 0078-0470 | Exjade | deferasirox | 
| 0078-0654 | Jadenu | deferasirox | 
| 0078-0655 | Jadenu | deferasirox | 
| 0078-0656 | Jadenu | deferasirox | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  EXJADE  88575851  not registered Live/Pending | QINGDAO YUZHUO COSMETIC PRODUCTS CO., LTD 2019-08-12 | 
|  EXJADE  78304307  2875038 Live/Registered | NOVARTIS AG 2003-09-23 | 
|  EXJADE  78089460  2773531 Dead/Cancelled | Novartis AG 2001-10-22 |